Country: Canada
Language: English
Source: Health Canada
OLMESARTAN MEDOXOMIL
APOTEX INC
C09CA08
OLMESARTAN MEDOXOMIL
20MG
TABLET
OLMESARTAN MEDOXOMIL 20MG
ORAL
15G/50G
Prescription
ANGIOTENSIN II RECEPTOR ANTAGONISTS
Active ingredient group (AIG) number: 0152496002; AHFS:
APPROVED
2017-05-01
_APO-OL MESARTAN _ _ _ _Page 1 of 33 _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR APO-OLMESARTAN Olmesartan Medoxomil Tablets 20 mg and 40 mg, Oral USP Angiotensin II AT 1 Receptor Blocker Apotex Inc. 150 Signet Drive Toronto, Ontario M9L 1T9 Date of Initial Authorization: May 01, 2017 Date of Revision: August 3, 2022 Submission Control Number: 261965 _APO-OL MESARTAN _ _ _ _Page 2 of 33 _ RECENT MAJOR LABEL CHANGES 2 CONTRAINDICATIONS, Pregnancy and Breastfeeding 08/2022 7 Warnings and Precautions, 7.1 Special Populations, 7.1.1 Pregnant women 08/2022 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ..............................................................................................2 PART I: HEALTH PROFESSIONAL INFORMATION .........................................................................4 1 INDICATIONS.....................................................................................................................4 1.1 Pediatrics..................................................................................................................4 1.2 Geriatrics ..................................................................................................................4 2 CONTRAINDICATIONS........................................................................................................4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ...................................................................5 4 DOSAGE AND ADMINISTRATION........................................................................................5 4.1 Dosing Considerations...............................................................................................5 4.2 Recommended Dose and Dosage Adjustment ............................................................6 4.3 Reconstitution ..........................................................................................................6 4.4 Administration ..... Read the complete document